BioAtla, a San Diego-Beijing biotech, could earn over $1 billion in a complicated deal with Pfizer that combines cancer drug technology from both companies; Jiangsu Hansoh Pharma is planning a $1.5 billion IPO in Hong Kong; Pharmaron raised more than $280 million in a funding led by China investors for its Beijing-US CRO operations; Akeso Biopharma of Zhongshan out-licensed global rights for an immuno-oncology antibody to Merck in a $200 million deal; Hutchison China MediTech sold land rights to the Shanghai government for $105 million; ASLAN Pharma of Singapore raised $34 million in a Series C round to underwrite clinical trial costs; Shanghai’s Luqa Pharma acquired greater China rights for a vitiligo treatment from Laboratoires Genevrier; Luye Medical Group paid $688 million to acquire Healthe Care Australia, a chain of 17 Australian hospitals; BeiGene of Beijing reported early positive data from a Phase I trial of its BTK inhibitor; Sinovac Biotech received approval to begin clinical trials of its Sabin Inactivated Polio Vaccine; and WuXi PharmaTech and PRA split their clinical-stage China CRO joint venture, with WuXi taking the CRO’s China operations and PRA owning the Hong Kong business.
